The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it

Annals of Neurology - Tập 32 Số 6 - Trang 804-812 - 1992
S Fahn1, Gerald Cohen2
1Department of Neurology, Columbia University College of Physicians and Surgeons, Mount Sinai School of Medicine, New York, NY.
2Department of Neurology and Fishberg Center for Neurobiology, Mount Sinai School of Medicine, New York, NY

Tóm tắt

AbstractOxidant stress, due to the formation of hydrogen peroxide and oxygen‐derived free radicals, can cause cell damage due to chain reactions of membrane lipid peroxidation. Because the substantia nigra is rich in dopamine, which can undergo both enzymatic oxidation via monoamine oxidase and nonenzymatic autoxidation, hydrogen peroxide and oxyradicals (superoxide anion radical and hydroxyl radical) are generated in this midbrain nucleus. Although proof that oxidant stress actually causes the loss of monoaminergic neurons in patients with Parkinson's disease is lacking, there is a considerable body of evidence from studies in both animals and humans that support the concept. (1) Neurotoxins that selectively destroy the dopaminergic neurons in the nigra, such as 6‐hydroxydopamine and 1‐methyl‐4‐phenyl‐l,2,3,6‐tetrahydropyridine (MPTP), appear to act via oxidant stress. (2) The substantia nigra of patients with Parkinson's disease reveals evidence of oxidant stress by the findings of increased lipid peroxidation and decreased reduced glutathione. (3) Total iron is increased and ferritin is reduced in the substantia nigra pars compacta in patients with Parkinson's disease. This combination suggests that this transition metal is in a low molecular weight form, capable of catalyzing nonenzymatic oxidative reactions, especially the conversion of hydrogen peroxide to hydroxyl radical, which is the most reactive of the oxygen radicals. (4) Neuromelanin, a product of dopamine autoxidation, can serve as a reservoir for iron, promoting the generation of oxyradicals. (5) Antioxidant defense mechanisms appear to be reduced in the parkinsonian substantia nigra with the findings of decreased activities of glutathione peroxidase and catalase. (6) The recent findings of decreased activity of NADH‐CoQ reductase, a mitochondrial complex I enzyme, in substantia nigra and platelets in patients with Parkinson's disease can also be interpreted to be a cause or product of oxidant stress. The identical enzyme abnormality occurs with MPTP toxicity, and this has been associated with increased superoxide anion radical formation. Moreover, mice with increased activity of superoxide dismutase are protected against MPTP toxicity. The evidence favoring the oxidant stress hypothesis is persuasive, but not yet fully established. We believe that this is the best hypothesis available at present.

Từ khóa


Tài liệu tham khảo

10.1016/0021-9681(63)90098-5

10.1136/jnnp.51.6.753

10.1212/WNL.33.7.815

10.1002/mds.870050302

10.1212/WNL.34.10.1354

10.1002/ana.410160303

10.1017/S0317167100037835

10.1017/S0317167100031826

10.1001/archneur.1991.00530210029018

10.1212/WNL.35.7.949

10.1002/mds.870040504

Duvoisin RC, 1982, Movement disorders, 8

10.1056/NEJM198510313131813

10.1016/S0140-6736(83)90802-4

CohenG. The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence.Neural Transm1983; (suppl 19):89–103

10.1016/0047-6374(83)90074-X

Graham DG, 1978, Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones, Mol Pharmacol, 14, 633

10.1111/j.1749-6632.1989.tb14919.x

10.1111/j.1600-0404.1989.tb01779.x

Olanow CW, 1990, Oxidation reactions in Parkinson's disease, Neurology, 40, 32

10.1111/j.1600-0404.1991.tb05013.x

10.3109/00207459109150342

10.1016/S0025-6196(12)64861-7

10.7326/0003-4819-107-4-526

10.1073/pnas.86.4.1398

10.1111/j.1600-0404.1989.tb01782.x

10.1038/334345a0

10.1111/j.1600-0404.1991.tb05021.x

10.1111/j.1471-4159.1990.tb04183.x

Youdim MBH, 1988, Brain iron: neurochemical and behavioural aspects

Graham DG, 1979, On the origin and significance of neuromelanin, Arch Pathol Lab Med, 103, 359

Kostrzewa RM, 1974, Pharmacological actions of 6‐hydroxydopamine, Pharmacol Rev, 26, 199

10.1016/0006-8993(73)90791-9

10.1016/0361-9230(91)90242-C

10.1016/0014-2999(77)90256-4

10.1126/science.181.4098.456

Cohen G, 1974, The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6‐hydroxydopamine, dialuric acid, and related cytotoxic agents, Biol Chem, 249, 2447, 10.1016/S0021-9258(19)42751-8

Cohen G, 1976, Destruction of sympathetic nerve terminals by 6‐hydroxydopamine: protection by 1‐phenyl‐3‐(2‐thiazolyl)‐2‐thiourea, diethyldithiocarbamate, methimazole, cysteamine, ethanol and n‐butanol, J Pharmacol Exp Ther, 199, 336

10.1212/WNL.35.7.949

Langston JW, 1987, Movement disorders 2, 73

10.1016/0006-291X(90)90498-C

Przedborski S, 1992, Transgenicmice with increased Cu/Zn‐superoxide dismutase activity are resistant to AT‐methyl‐4‐phenyl‐l,2,3,6‐tetrahydropyridine–induced neurotoxicity, J Neurosci, 12, 1658, 10.1523/JNEUROSCI.12-05-01658.1992

10.1111/j.1471-4159.1990.tb02325.x

10.1002/jnr.490260405

10.1016/0022-510X(91)90046-A

10.1002/mds.870070105

10.1016/0014-4886(91)90081-M

10.1016/0014-4886(90)90031-M

10.1007/BF00231044

BluntSB JennerP MarsdenCD.Suppressive effect of L‐DOPA on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6‐hydroxy dopamine. Mov Disord1993(in press)

Spina MB, 1988, Exposure of striatal synaptosomes to L‐DOPA increases the level of oxidized glutathione, J Pharmacol Exp Ther, 247, 502

10.1073/pnas.86.4.1398

10.1002/ana.410260518

Brody H, 1976, Neurobiology of aging, 177

10.1001/archneur.1977.00500130053010

10.1007/BF01249444

Cote LJ, 1983, Biochemical changes in normal aging, in human brain, Adv Neurol, 88, 19

McGeer EG, 1978, Alzheimer's disease: senile dementia and related disorders, 427

10.1016/0022-510X(73)90175-5

10.1136/jnnp.54.5.388

10.1002/ana.410240415

10.1016/0304-3940(85)90078-3

10.1016/0304-3940(82)90390-1

10.1111/j.1471-4159.1989.tb09150.x

10.1016/0304-3940(86)90320-4

10.1016/0304-3940(87)90061-9

10.1001/archneur.1975.00490440064010

10.1111/j.1471-4159.1989.tb09133.x

10.1111/j.1471-4159.1989.tb07264.x

10.1093/brain/114.4.1953

10.1111/j.1471-4159.1991.tb02017.x

10.1111/j.1471-4159.1990.tb08814.x

10.1016/B978-0-12-364931-7.50006-9

10.1111/j.1471-4159.1989.tb11759.x

10.1016/0022-510X(88)90108-6

10.1111/j.1471-4159.1990.tb05809.x

10.1002/ana.410300409

10.1002/mds.870050406

10.1111/j.1471-4159.1990.tb04973.x

10.1002/ana.410260606

10.1016/0006-291X(89)91141-8

10.1056/NEJM198911163212004

10.1126/science.2502843

10.1212/WNL.42.2.339

10.1126/science.3875898

10.1016/0306-4522(89)90218-2

10.1212/WNL.41.6.859

10.1016/0006-8993(80)90871-9

Hornykiewicz O, 1982, Movement disorders, 41

10.1136/jnnp.55.3.181

10.1212/WNL.31.9.1194

10.1111/j.1471-4159.1984.tb12834.x

Thông tin
Thông tin xuất bản

Annals of Neurology

Tập 32 Số 6

804-812

Thông tin tác giả